Highest-materiality recent filing
Curis Q1 net loss $24.2M, no revenue; cash $15M; clinical milestones ahead
Net loss of $24.2M ($1.25 per share) vs $10.6M loss in Q1 2025; EPS unchanged due to higher share count.
Curis receives Nasdaq delisting notice due to bid price below $1.00 for 30 days
Received Delist Determination Letter from Nasdaq on April 27, 2026.
Curis Q4 net income $19.4M on Erivedge gain; PIPE raises $20.2M initial
FY2025 net loss $7.6M ($0.58/shr) vs $43.4M ($6.88/shr) in FY2024; Q4 net income $19.4M ($1.23/shr).
Curis shareholders approve authorized share increase from 73.3M to 288.8M and 2026 Incentive Plan
Authorized common stock increased from 68.3M to 283.8M; total capital stock from 73.3M to 288.8M, effective March 17, 2026.
Curis raises up to $80.8M in PIPE financing; extends cash runway into 2027
Initial gross proceeds of ~$20.2M from sale of Series B Preferred Stock and warrants; potential total up to ~$80.8M if warrants exercised.
Curis sells Erivedge royalty interest for $2.5M; pro forma shows $28M gain
Sold Curis Royalty LLC to Oberland Capital for $2.5M upfront plus release of $28.6M liability.
Curis sells Erivedge royalty rights to Oberland for $2.5M; Q3 net loss narrows to $7.7M
Sold Erivedge IP and license rights to Oberland affiliate for $2.5M upfront and release of future royalty liability.
Nasdaq grants Curis exception until Nov 14, 2025 to meet $35M MVLS rule
Company received Nasdaq delisting notice on Aug 21, 2025 for failing $35M market value requirement.
Curis receives Nasdaq delisting notice for market value below $35M; plans appeal
On Aug 21, 2025, Curis received Nasdaq delisting notice for failing MVLS Requirement (market value <$35M for 30 consecutive days).
Curis Q2 2025 net loss $8.6M; cash runway extended to Q1 2026 via $6M offering
Net loss $8.6M ($0.68/sh) vs $11.8M ($2.03/sh) in Q2 2024; revenue $2.7M from Erivedge royalties.
Curis raises $7.0M in registered direct & private placement; cash runway into Q1 2026
Gross proceeds ~$7.0M from sale of 1,538,460 shares and warrants; combined price $2.275/share + warrant.
Authorized common shares increased from 34.2M to 68.3M; total capital stock from 39.2M to 73.3M.
Curis Q1 net loss $10.6M, appoints Dr. Hamdy CMO, emavusertib progress
Net loss $10.6M ($1.25/share); cash $20.3M; runway into Q4 2025.
Curis gains FDA & EMA support for accelerated approval of emavusertib in PCNSL
FDA and EMA agree TakeAim Lymphoma study may support accelerated approval path for PCNSL.
Curis raises ~$10M; FY2024 net loss $43.4M; FDA/EMA see path for PCNSL drug
Gross proceeds ~$10M from sale of 1.97M shares and pre-funded warrants for 2.18M shares, plus common warrants for 8.32M shares at $2.41.
Curis receives Nasdaq notice of non-compliance with market value listing requirement
Market value of listed securities below $35M for 30 consecutive business days as of Feb 21, 2025.
Curis Q3 net loss narrows to $10.1M; emavusertib shows durable responses in BTKi-progressed PCNSL
Net loss of $10.1M ($1.70 per share) vs $12.2M ($2.13) in Q3 2023; nine-month net loss $33.8M.
Curis raises $12.1M via registered direct offering and concurrent private placement
Issued 2,398,414 shares of common stock and unregistered warrants for 2,398,414 shares at exercise price $4.92.
Curis Q2 net loss $11.8M; emavusertib gets EU ODD for PCNSL
Net loss of $11.8M ($2.03/sh) vs $12.0M ($2.47) in Q2 2023; revenue $2.5M from Erivedge royalties.
Curis cuts workforce ~30%, focuses on combo studies; cash runway into 2025
Board approved ~30% workforce reduction as monotherapy trials near completion.
Curis expands TakeAim Leukemia study to 30 patients; 6/11 FLT3m and 4/18 SFm respond
TakeAim Leukemia dataset expanded from 5 to 30 R/R AML patients (25 new) with emavusertib monotherapy at 300 mg BID.
Curis Q4 2023 net loss $11.7M ($2.03/sh); cash $56.3M, clinical data from ASH shows CRs
Net loss for Q4 2023 was $11.7M ($2.03/share) vs $11.3M ($2.35/share) in Q4 2022.
Curis stockholders approve 1-for-20 reverse stock split and increase in authorized shares
Stockholders approved increase in authorized common shares from 227,812,500 to 455,625,000 at Special Meeting on Sept 26.
Curis approves 1-for-20 reverse stock split; authorized common shares set at 22.78M after amendments
Special meeting on Sept 26, 2023 approved 1-for-20 reverse stock split; effective Sept 28, trading on split-adjusted basis Sept 29.
Curis Q2 net loss $12.0M ($0.12/sh); FDA lifts partial clinical hold on TakeAim Leukemia study
Net loss $12.0M ($0.12/sh) vs $15.9M ($0.17/sh) in Q2 2022; six-month net loss $23.5M ($0.24/sh).
FDA lifts partial clinical hold on Curis leukemia study; RP2D set at 300 mg BID
FDA removed partial clinical hold on TakeAim Leukemia Phase 1/2 study of emavusertib (CA-4948).
Curis prices $15.1M registered direct offering of 18.4M shares at $0.82/share
Offering led by existing investors; 18.4M shares sold at $0.82 per share.
Curis Q1 net loss narrows to $11.6M; enrolls 9 patients for emavusertib; new CDO
Net loss $11.6M ($0.12/share) vs $16.1M ($0.18) YoY; revenue $2.3M, up from $2.1M.
Transfer from Nasdaq Global Market to Nasdaq Capital Market effective April 24, 2023.
Curis completes FDA-requested enrollment for emavusertib; FY2022 net loss $56.7M
Completed enrollment of 9 additional patients at 200mg BID for TakeAim Leukemia study ahead of schedule; expects data in Q2, FDA meeting in Q3 for partial clinical hold resolution.
Curis Q3 net loss $13.3M, cuts ~30% of workforce to focus on emavusertib, cash runway into 2025
Net loss of $13.3M ($0.14/shr) vs $11.1M ($0.12/shr) in Q3 2021; revenues $2.8M.
Curis receives Nasdaq deficiency notice for bid price below $1.00; 180-day cure period
On Oct 21, 2022, Nasdaq notified Curis its common stock bid price closed below $1.00 for 30 consecutive business days, violating Listing Rule 5450(a)(1).
Director Lori Kunkel resigns from Curis board citing fundamental disagreement on operations
Resignation effective September 30, 2022; she served on Nominating/Corporate Governance and chaired Clinical Program Committee.
FDA allows Curis to resume enrollment in Phase 1a of emavusertib leukemia study
FDA removed partial clinical hold on monotherapy dose-finding (Phase 1a) of TakeAim Leukemia study after reviewing rhabdomyolysis data.
FDA lifts partial clinical hold on Curis's TakeAim Lymphoma study of emavusertib
FDA lifted partial clinical hold on TakeAim Lymphoma Phase 1/2 study; enrollment to resume Q3 2022.
Net loss of $15.9M ($0.17/sh) vs $10.8M ($0.12) in Q2 2021; revenue flat at $2.4M.
Curis CFO William Steinkrauss resigns effective Aug 5, 2022; consulting transition
William Steinkrauss notified Curis of resignation on June 27, 2022 to pursue entrepreneurial opportunity.
Curis Q1 net loss $16.1M; cash $120.7M; emavusertib studies on partial clinical hold
Net loss $16.1M ($0.18/sh) vs $9.9M in Q1 2021; revenue $2.1M unchanged.
FDA partial clinical hold on Curis' TakeAim Lymphoma study; no new enrollment
FDA placed partial clinical hold on Phase 1/2 TakeAim Lymphoma study of emavusertib in B-cell malignancies.
FDA partial clinical hold on Curis leukemia study after patient death; lymphoma study paused
FDA partial clinical hold on TakeAim Leukemia Phase 1/2a (NCT04278768); no new patients enrolled.
On October 12, 2022 , the Board of Directors (“Board”) of Curis, Inc. (the “Company”) elected Anne E. Borgman, M.D., to serve as a class I director until the 2024 Annual Meeting of Stockholders and thereafter until her successor is duly elected and qualified.
On September 19, 2022 , Lori A. Kunkel, M.D. submitted her written resignation (the “Resignation Letter”) from the Board of Directors (the “Board”) of Curis, Inc. (the “Company”) effective September 30, 2022.
On August 4, 2022, the Board of Directors (the “Board”) of the Company appointed Diantha Duvall to the position of chief financial officer, treasurer, assistant secretary, principal financial officer and principal accounting officer of the Company effective as of August 5, 2022.
On June 27, 2022, William Steinkrauss notified Curis, Inc. (the “Company”) of his intention to resign from his role as Chief Financial Officer and Chief Administrative Officer (Principal Financial and Accounting Officer) in order to pursue an entrepreneurial opportunity in consulting.
On December 2, 2021, the Board of Directors (“Board”) of Curis, Inc. (the “Company”) elected John A. Hohneker, M.D., to serve as a class II director until the 2022 Annual Meeting of Stockholders and thereafter until his successor is duly elected and qualified.
Max materiality 0.85 · Median 0.70 · Most common event earnings